Cipla launch drug Cipremi in India for emergency use in the treatment of COVID-19 patients

Cipla launch drug Cipremi in India for emergency use in the treatment of COVID-19 patients

YD News | Cipla launch drug Cipremi in India

Cipla Limited has announced the launch of its generic version of antiviral drug Remdesivir for emergency use in the treatment of Covid-19 patients. The new drug will be sold under the brand name Cipremi.

As the Cipla launch drug Cipremi, This antiviral drug Cipremi is the latest to join Glenmark’s Fabiflu and Hetero’s Covifor to treat Covid-19 patients in India.

“The Union Health Ministry included the use of antiviral drug Remdesivir as part of “investigational therapy” in India”

The Union Health Ministry included the use of antiviral drug Remdesivir as part of “investigational therapy” in India, last week, only. But for restricted emergency-use in its updated Clinical Management Protocol for Covid-19 patients. Off-label application of immunomodulator tocilizumab and convalescent plasma therapy for treating coronavirus patients in moderate stage of criticality was also approved by the ministry.

Remdesivir, happens to be the only USFDA approved Emergency Use Authorisation (EUA) treatment for adults and children hospitalised with suspected or laboratory confirmed coronavirus infection.

“Gilead Sciences Inc extended a voluntary non-exclusive license to India-based Cipla to manufacture and market the generic version of Remdesivr called Cipremi”

When nearly 200 countries across the globe are grappling with the Covid-19 pandemic, Gilead Sciences Inc extended a voluntary non-exclusive license to India-based Cipla to manufacture and market the generic version of Remdesivir called Cipremi.

On 13th of June Cipla official twitter handle also twitted, #Cipla enters into a licensing agreement with #Gilead to expand access to #COVID19 treatment. and that was also re-twitted by Umang Vohra, MD and Global CEO of Cipla limited.

“Cipla Limited has been granted regulatory approval by the Drug Controller General of India(DCGI)”

Pharma firm Cipla Limited has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent medical need with a surge in Covid-19 cases in India, which have crossed the 4,00,000-mark.

Prices of the drug in the Indian market are yet to be announced by Cipla.

“As part of a risk management plan, Cipla will provide training on the use of the drug, inform patients for consent documents, conduct post-marketing surveillance as well as to conduct a Phase-IV clinical trial on Indian patients,” the company said in a statement.

“Cipla appreciates the strong partnership with Gilead to bring Remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by the Covid-19 pandemic, and this launch is a significant milestone in that direction,” MD and Global CEO Umang Vohra said

Coronavirus patients can get quick access to this treatment and in anticipation of high demand, Cipla will be commercializing Remdesivir through its own facilities and partnered sites, the company statement said.

This drug will be supplied through the government and open market channels to ensure equitable distribution, the statement read.

Also read: Glenmark launches drug Fabiflu in India after DCGI approval, for treatment of mild to moderate COVID-19 patients, MRP at Rs 103 per tablet

Leave a Reply

Your email address will not be published. Required fields are marked *